Figure 2 | Scientific Reports

Figure 2

From: Cyclophosphamide exposure assessed with the biomarker phosphoramide mustard-hemoglobin in breast cancer patients: The TailorDose I study

Figure 2

Mean (± standard deviation) levels of phosphoramide mustard-hemoglobin (PAM-Hb) for patients receiving 500 mg (C500 group) or 600 mg (C600 group) cyclophosphamide per body surface area unit during three treatment courses and the inter-individual difference per course. Difference between mean PAM-Hb levels between C500 and C600 groups was compared with an independent sample t-test. Patients were included until they changed cyclophosphamide dose or stopped the treatment.

Back to article page